The Asia Pacific NGS Market which was worth USD 0.8 billion by the end of 2019 is poised to reach USD 2.49 billion by 2024 at a CAGR of 25.35%. The Asia-Pacific market is expected to grow at a considerable rate throughout the forecast period. The expected growth can be attributed to Asian companies and government agencies that are working to boost their genomics industry and revenue generation in this area.
The Asia-Pacific region is showcasing healthy growth due to the innovation and increased funding provided by governments and private organizations. Increased investment by biotechnology and pharmaceutical companies is also expected to increase market demand. However, North America dominated the market in 2018 with the largest share and is expected to maintain this trend throughout the forecast period. This is due to increased investment in R & D activities due to the spread of cancer and infectious diseases. Also, the development of NGS bioinformatics solutions and the presence of key players in the region will further accelerate market growth.
Asia presents significant opportunities for the investors/venture capitalists as the developed markets are saturated. The presence of noteworthy developments by China and Japan for the integration of new technologies and the development of healthcare is majorly driving the Asia Pacific Market. R&D and clinical development frameworks of countries such as India and Australia have composed the Asia Pacific market to witness a lucrative growth throughout the forecast period. Rise in growth of personalized medicine, development in pre-sequencing and NGS bioinformatics solutions and cloud computing, growth in the Asia-Pacific population, increasing incidence of infectious diseases are few factors driving the market growth.
In addition, anticipated decrease in the prices of genome sequencing due to the development of rapid, high capacity whole genome sequencers by key players is expected to have an optimistic effect on market penetration rates over the few years. However, the storage and management of enormous data generated by sequencing and its interpretation, high reliability on grants & funding from the government and fall in capital expenditure from academic institutions are some of the challenges for Asia-Pacific next-generation sequencing market
This research report segmented and sub-segmented into the following categories:
Regionally, as the domestic market expands, Asian companies are adopting various marketing strategies to expand their marketing operations in other regional markets. BGI acquired Complete Genomics, an Asia company that provides a next-generation sequencing platform for DNA for human genome analysis. Similarly, China partnered with the UK in December 2017 to expand the country's space for science and innovation.
Leading companies in the Asia Pacific Next Generation Sequencing (NGS) Market are Illumina Incorporated, Thermo Fischer Scientific, Life Sciences (Roche), Pacific Biosciences, Life Technologies Corp. (Thermo Fischer Scientific), Macrogen Inc, Partek Inc., Genomatix Software GmbH, Perkin Elmer inc., GATC Biotech Ag, Agilent Technologies Inc., Biomatters Ltd., CLC Bio (Qiagen), BGI (Beijing Genomics Institute), Oxford Nanopore Technologies Ltd., DNASTAR Inc., Knome Inc. and Qiagen N.V.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Analysis Design
2.3 Research Phases
2.3.1 Secondary Research
2.3.2 Primary Research
2.3.3 Econometric Modelling
2.3.4 Expert Validation
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Product
5.1.1 Software
5.1.2 Services
5.2 By Technology
5.2.1 Whole Targeted Re-Sequencing
5.2.2 Genome Sequencing
5.2.3 De Novo Sequencing
5.2.4 Exome Sequencing
5.2.5 RNA-Seq
5.2.6 ChIP-Seq
5.2.7 Methyl-Seq
5.3 By Application
5.3.1 Diagnostics
5.3.2 Drug Discovery
5.3.3 Biomarker Discovery
5.3.4 Personalized Medicine
5.3.5 Agriculture and Animals Research
6. Geographical Analysis
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Illumina, Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Thermo Fischer Scientific
8.3 Life Sciences (Roche)
8.4 Pacific Biosciences
8.5 Macrogen Inc.
8.6 Partek Inc.
8.7 Genomatix Software GmbH
8.8 Perkin Elmer inc.
8.9 GATC Biotech Ag
8.10 Agilent Technologies Inc.
8.11 Biomatters Ltd.
8.12 CLC Bio (Qiagen)
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Aug 2019
Download Sample
